伏立诺他临床应用新进展  

New progress of the clinical application of vorinostat

作　　者：郑亚东 杨平传 赵雪 

机构地区：[1]国药一心制药有限公司,长春130616

出　　处：《中国新药杂志》2015年第8期900-903,共4页Chinese Journal of New Drugs

摘　　要：伏立诺他作为一种组蛋白去乙酰化酶抑制剂,已在2006年被美国FDA批准用于皮肤T细胞淋巴瘤(CTCL)的治疗,近年来随着研究的不断深入,伏立诺他在其他肿瘤治疗领域也有了较好的疗效,伏立诺他联合吉妥单抗及阿扎胞苷治疗老年复发性或难治性急性髓系细胞白血病(AML)有效率可达40%,联合地西他滨治疗复发性或难治性急性淋巴细胞白血病(AL)有效率为46.2%,联合硼替佐米治疗多发性骨髓瘤(MM)无疾病进展生存期为7.63个月,另外在晚期乳腺癌和骨髓移植患者免疫功能改善方面都有较好的作用。本文通过对伏立诺他近期国外的临床应用进行了文献检索,并将其应用新进展进行综述。Vorinostat, a pan-histone deacetylase inhibitor （HDACI） , was approved by the US Food and Drug Administration （FDA） for use in patients with cutaneous T-cell lymphoma （CTCL） in 2006. In recent years, with the deepening of the research, vorinostat has good efficacy in the treatment for other cancers. Vorinostat in combination with gemtuzumab ozogamicin and azacitidinecan improves effective rates to 40% in the treatment of elderly patients with relapsed orrefractory acute myelogenous leukemia （AML）. Vorinostat in combination with decitabine can improve effective rates to 46.2% in the treatment of relapsed or refractory acute lymphoblastic leukemia （AL）. Vorinostat in combination with bortezomib intreatment for multiple myeloma （MM） may prolong progression-free survival to 7.63 months. Furthermore, vorinostat can effectively improve the immune function of patients with advanced breast cancer and bone marrow transplant. In this article, we summarized progress of vorinostat applications through reviewing foreign literature in recent years.

关 键 词：伏立诺他 皮肤T细胞淋巴瘤 急性髓系细胞白血病 急性淋巴细胞白血病 多发性骨髓瘤 乳腺癌 骨髓移植 

分 类 号：R977.3[医药卫生—药品]